Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer - PubMed (original) (raw)
Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer
Karlene Smith et al. Cancer Res. 2005.
Abstract
Inactivating mutations in the von Hippel-Lindau (VHL) tumor suppressor gene are associated with clear cell renal cell carcinoma (VHL-/- RCC), the most frequent malignancy of the human kidney. The VHL protein targets the alpha subunits of hypoxia-inducible factor (HIF) transcription factor for ubiquitination and degradation. VHL-/- RCC cells fail to degrade HIF resulting in the constitutive activation of its target genes, a process that is required for tumorigenesis. We recently reported that HIF activates the transforming growth factor-alpha/epidermal growth factor receptor (TGF-alpha/EGFR) pathway in VHL-defective RCC cells. Here, we show that short hairpin RNA (shRNA)-mediated inhibition of EGFR is sufficient to abolish HIF-dependent tumorigenesis in multiple VHL-/- RCC cell lines. The 2alpha form of HIF (HIF-2alpha), but not HIF-1alpha, drives in vitro and in vivo tumorigenesis of VHL-/- RCC cells by specifically activating the TGF-alpha/EGFR pathway. Transient incubation of VHL-/- RCC cell lines with small interfering RNA directed against EGFR prevents autonomous growth in two-dimensional culture as well as the ability of these cells to form dense spheroids in a three-dimensional in vitro tumor assay. Stable expression of shRNA against EGFR does not alter characteristics associated with VHL loss including constitutive production of HIF targets and defects in fibronectin deposition. In spite of this, silencing of EGFR efficiently abolishes in vivo tumor growth of VHL loss RCC cells. These data identify EGFR as a critical determinant of HIF-2alpha-dependent tumorigenesis and show at the molecular level that EGFR remains a credible target for therapeutic strategies against VHL-/- renal carcinoma.
Similar articles
- Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA, Lee S. Gunaratnam L, et al. J Biol Chem. 2003 Nov 7;278(45):44966-74. doi: 10.1074/jbc.M305502200. Epub 2003 Aug 27. J Biol Chem. 2003. PMID: 12944410 - TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
Shang D, Liu Y, Yang P, Chen Y, Tian Y. Shang D, et al. Urology. 2012 Apr;79(4):966.e1-7. doi: 10.1016/j.urology.2011.12.011. Epub 2012 Feb 15. Urology. 2012. PMID: 22341602 - The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG Jr. Kaelin WG Jr. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S. doi: 10.1158/1078-0432.CCR-sup-040025. Clin Cancer Res. 2004. PMID: 15448019 Review. - VHL and HIF signalling in renal cell carcinogenesis.
Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP. Baldewijns MM, et al. J Pathol. 2010 Jun;221(2):125-38. doi: 10.1002/path.2689. J Pathol. 2010. PMID: 20225241 Review.
Cited by
- Deubiquitinase OTUD6A Regulates Innate Immune Response via Targeting UBC13.
Li Z, Li G, Li Y, Luo Y, Jiang Y, Zhang Z, Zhou Z, Liu S, Wu C, You F. Li Z, et al. Viruses. 2023 Aug 18;15(8):1761. doi: 10.3390/v15081761. Viruses. 2023. PMID: 37632103 Free PMC article. - von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
Shirole NH, Kaelin WG Jr. Shirole NH, et al. Hematol Oncol Clin North Am. 2023 Oct;37(5):809-825. doi: 10.1016/j.hoc.2023.04.011. Epub 2023 Jun 1. Hematol Oncol Clin North Am. 2023. PMID: 37270382 Free PMC article. Review. - Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance.
Mazumder S, Higgins PJ, Samarakoon R. Mazumder S, et al. Cancers (Basel). 2023 Feb 19;15(4):1316. doi: 10.3390/cancers15041316. Cancers (Basel). 2023. PMID: 36831657 Free PMC article. Review. - Notch signaling, hypoxia, and cancer.
Guo M, Niu Y, Xie M, Liu X, Li X. Guo M, et al. Front Oncol. 2023 Jan 31;13:1078768. doi: 10.3389/fonc.2023.1078768. eCollection 2023. Front Oncol. 2023. PMID: 36798826 Free PMC article. Review. - miRNA-150_R-1 mediates the HIF-1/ErbB signaling pathway to regulate the adhesion of endometrial epithelial cells in cows experiencing retained placenta.
Lv C, Li Z, Wang Q, Wang Y, Zhao X, Zhang Y. Lv C, et al. Front Vet Sci. 2022 Oct 17;9:1037880. doi: 10.3389/fvets.2022.1037880. eCollection 2022. Front Vet Sci. 2022. PMID: 36325096 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous